Common Contracts
3 similar Master Collaboration Agreement contracts by Prothena Corp PLC
EX-10.3 5 d583971dex103.htm EX-10.3 CONFIDENTIAL EXECUTION VERSIONMaster Collaboration Agreement • May 5th, 2020 • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
MASTER COLLABORATION AGREEMENT by and among PROTHENA BIOSCIENCES LIMITED And CELGENE SWITZERLAND LLC Dated as of March 20, 2018Master Collaboration Agreement • August 17th, 2018 • Prothena Corp PLC • Pharmaceutical preparations • New York
This U.S. LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of , 20 (the “Effective Date”) by and between Prothena Biosciences Limited, an Irish limited company (“Prothena”) and Celgene Switzerland LLC, a Delaware limited liability company (“Celgene”)3. Celgene and Prothena are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.
MASTER COLLABORATION AGREEMENT by and among PROTHENA BIOSCIENCES LIMITED And CELGENE SWITZERLAND LLC Dated as of March 20, 2018Master Collaboration Agreement • May 9th, 2018 • Prothena Corp PLC • Pharmaceutical preparations • New York
This MASTER COLLABORATION AGREEMENT (this “Agreement”) is entered into and made effective as of March 20, 2018 (the “Effective Date”) by and among Prothena Biosciences Limited, an Irish limited company (“Prothena”) and Celgene Switzerland LLC, a Delaware limited liability company (“Celgene”). Celgene and Prothena are each referred to herein by name or as a “Party”, or, collectively, as the “Parties”.
